David Peloquin
As seen in:
Nature,
Science Magazine,
Legaltech News,
A Health Podyssey,
Health Affairs,
Bloomberg Law,
Law360,
JD Supra,
Lexology,
Bloomberg Industry Group
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by David Peloquin
DoD Removes WuXi AppTec from the 1260H List
Executive Summary On November 10, 2026, the Department of Defense (DoD) removed WuXi AppTec Co., Ltd.
Federal Court Enjoins DoD Designation of WuXi AppTec as a "Chinese Military Company" Under Section 1260H | JD Supra
Executive Summary On August 7, 2026, Chief Judge James E. Boasberg of the U.S. District Court for the District of Columbia granted a preliminary injunction barring the Department of Defense from enforcing its designation of WuXi AppTec Co., Ltd. ("WuXi") as a "Chinese military company" under Section 1260H of the National Defense Authorization Act for Fiscal Year 2021 (the "1260H List").
HHS “Operation TrialBlazer” and the Future of U.S. Clinical Trial Access, Payment, and Infrastructure Reform
On June 22, 2026, the U.S. Department of Health and Human Services (HHS) “Operation TrialBlazer”, a coordinated, department-wide initiative to restore U.S. leadership in clinical research and development (the “Initiative”).1 The Initiative spans multiple HHS divisions: the Food and Drug Administration (FDA), the National Institutes of Health (NIH) (including the National Center for Advancing Translational Sciences (NCATS) and the National Cancer Institute (NCI)), the Advanced Research...
NIH Prohibits Use of Federal Funds for Research Involving Human Fetal Tissue from Elective Abortions | JD Supra
On January 22, 2026, the National Institutes of Health (NIH) issued NOT-OD-26-028, prohibiting the use of NIH funds for research involving human fetal tissue (HFT) obtained from elective abortions (the Notice). This Notice is effective as of its publication date and supersedes certain previous NIH guidance on human fetal tissue research issued during the Biden Administration, including NOT-OD-21-111 and NOT-OD-19-128.
National Institutes of Health Announces New Restrictions on the Sharing of Human Biospecimens with China and other “Countries of Concern” | JD Supra
On September 24, 2025, the National Institutes of Health (“NIH”) published a policy entitled “Enhancing Security Measures for Human Biospecimens” (the “Policy”).
National Institutes of Health Announces New Restrictions on the Sharing of Human Biospecimens with China and other “Countries of Concern”
On September 24, 2025, the National Institutes of Health (“NIH”) published a policy entitled “Enhancing Security Measures for Human Biospecimens” (the “Policy”).
National Institutes Of Health Announces New Restrictions On The Sharing Of Human Biospecimens With China And Other "Countries Of Concern"
On September 24, 2025, the National Institutes of Health ("NIH") published a policy entitled "Enhancing Security Measures for Human Biospecimens" (the "Policy").
EXPERT INSIGHTS-NATIONAL INSTITUTES OF HEALTH ANNOUNCES NEW RESTRICTIONS ON THE SHARING OF HUMAN BIOSPECIMENS WITH CHINA AND OTHER ‘COUNTRIES OF CONCERN‘ | Secondary Sources | National | Westlaw Today
On September 24, 2025, the National Institutes of Health (NIH) published a policy entitled Enhancing Security Measures for Human Biospecimens (the Policy). The Policy is based on Executive Order 14117 ,...
It's All Relative: Analysing The CJEU's Judgment On The Scope Of Pseudonymous Personal Data
RG Ropes & Gray LLP More Ropes & Gray is a preeminent global law firm with approximately 1,400 lawyers and legal professionals serving clients in major centers of business, finance, technology and government. The firm has offices in New York, Washington, D.C., Boston, Chicago, San Francisco, Silicon Valley, London, Hong Kong, Shanghai, Tokyo and Seoul.
It's All Relative: Analysing The CJEU's Judgment On The Scope Of Pseudonymous Personal Data | JD Supra
In a decision with significant legal and operational ramifications for organisations of all shapes and sizes, the Court of Justice of the European Union (CJEU) last week confirmed that pseudonymised data will not always and for all parties constitute personal data for the purposes of the General Data Protection Regulation (GDPR).
HALT Fentanyl Act: Unpacking its Significant Reforms for Controlled Substance Research | JD Supra
On July 16, 2025, President Trump signed the Halt All Lethal Trafficking of Fentanyl (“HALT Fentanyl”) Act into law. The law permanently reclassifies “fentanyl-related substances” into Schedule I of the Controlled Substances Act (“CSA”), and much of the political commentary and media attention related to the legislation have focused on this specific provision and its potential impact on the nation’s fentanyl crisis.
In Bloomberg Law, David Peloquin Discusses Bulk Data Transfer Rule Enforcement
Ropes & Gray’s health care partner, David Peloquin, spoke with Bloomberg Law on the additional DOJ instructions regarding the Biden-era Executive Order 14117.
DOJ Bulk Data Final Rule Update | JD Supra
Yesterday, the Department of Justice’s (“DOJ”) Final Rule implementing former President Biden’s Executive Order 14117, “Preventing Access to Americans’ Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern” (the “Final Rule”) took effect.
Today, the Department of Justice’s (“DOJ”) Final Rule implementing former President Biden’s Executive Order 14117, “Preventing Access to Americans’ Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern” (the “Final Rule”) took effect.
In IAPP Article, David Peloquin and Jake Barr Discuss DOJ Rule Limiting Sensitive Data Transfers
In an International Association of Privacy Professionals (IAPP) article, health care partner David Peloquin and data, privacy and cybersecurity associate Jake Barr along with Legend Biotech Chief Privacy Officer and Assistant General Counsel Corey Dennis discuss the landmark rule limiting sensitive data transfers to “countries of concern.” The article reviews key aspects for health care and life sciences companies, key exemptions, and best practices to ensure compliance.
FDA And OHRP Issue Draft Guidance On Including Biopsies In Clinical Trials
On January 6, 2025, the U.S. Food and Drug Administration ("FDA") and the Office for Human Research Protections ("OHRP") issued a joint draft guidance on including tissue biopsies in clinical trials that evaluate FDA-regulated investigational medical products1 or are supported by the U.S. Department of Health and Human Services ("HHS").2 The draft guidance defines a biopsy as a procedure that acquires tissue from a trial participant as part of the clinical trial protocol.
FDA and OHRP Issue Draft Guidance on Including Biopsies in Clinical Trials | JD Supra
On January 6, 2025, the U.S. Food and Drug Administration (“FDA”) and the Office for Human Research Protections (“OHRP”) issued a joint draft guidance on including tissue biopsies in clinical trials that evaluate FDA-regulated investigational medical products1 or are supported by the U.S. Department of Health and Human Services (“HHS”).2 The draft guidance defines a biopsy as a procedure that acquires tissue from a trial participant as part of the clinical trial protocol.
DOJ Issues Final Rule Restricting Flow Of Bulk Sensitive Personal Data To China And Other Countries Of Concern
On January 8, 2025, the Department of Justice ("DOJ") published its Final Rule to implement President Biden's Executive Order 14117, "Preventing Access to Americans' Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern" (the "Final Rule"). This follows the DOJ's publication of its Notice of Proposed Rulemaking ("NPRM") in October 2024, and its Advance Notice of Proposed Rulemaking ("ANPRM") earlier in 2024.
On January 8, 2025, the Department of Justice (“DOJ”) published its Final Rule to implement President Biden’s Executive Order 14117, “Preventing Access to Americans’ Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern” (the “Final Rule”). This follows the DOJ’s publication of its Notice of Proposed Rulemaking (“NPRM”) in October 2024, and its Advance Notice of Proposed Rulemaking (“ANPRM”) earlier in 2024.
DOJ Issues Final Rule Restricting Flow of Bulk Sensitive Personal Data to China and Other Countries of Concern | JD Supra
On January 8, 2025, the Department of Justice (“DOJ”) published its Final Rule to implement President Biden’s Executive Order 14117, “Preventing Access to Americans’ Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern” (the “Final Rule”). This follows the DOJ’s publication of its Notice of Proposed Rulemaking (“NPRM”) in October 2024, and its Advance Notice of Proposed Rulemaking (“ANPRM”) earlier in 2024.
Clinical Trial Protocol Deviations: A New FDA Draft Guidance To Ring In The New Year
As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review boards ("IRBs") with defining, identifying, and reporting protocol deviations in clinical investigations ("Draft Guidance").
Clinical Trial Protocol Deviations: A New FDA Draft Guidance to Ring in the New Year | JD Supra
As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review boards (“IRBs”) with defining, identifying, and reporting protocol deviations in clinical investigations (“Draft Guidance”).
Non-binding Guidance: Clinical Trial Diversity in Focus | JD Supra
On this episode of Ropes & Gray’s podcast series Non-binding Guidance, health care partner David Peloquin and life sciences regulatory and compliance counsel Sarah Blankstein discuss the FDA's recent draft guidance on diversity action plans (DAPs) aimed at improving the enrollment of underrepresented populations in clinical studies.
Non-binding Guidance: Clinical Trial Diversity In Focus (Podcast)
On this episode of Ropes & Gray's podcast series Non-binding Guidance, health care partner David Peloquin and life sciences regulatory and compliance counsel Sarah Blankstein discuss the FDA's recent draft guidance on diversity action plans (DAPs) aimed at improving the enrollment of underrepresented populations in clinical studies.
DOJ Issues Notice Of Proposed Rulemaking To Restrict Flow Of Bulk Sensitive Personal Data To China And Other Countries Of Concern
RG Ropes & Gray LLP More Ropes & Gray is a preeminent global law firm with approximately 1,400 lawyers and legal professionals serving clients in major centers of business, finance, technology and government. The firm has offices in New York, Washington, D.C., Boston, Chicago, San Francisco, Silicon Valley, London, Hong Kong, Shanghai, Tokyo and Seoul.
Three Of A Kind: FDA Guidance Documents Provide Recommendations On Non-Traditional Clinical Trial Designs
RG Ropes & Gray LLP More Ropes & Gray is a preeminent global law firm with approximately 1,400 lawyers and legal professionals serving clients in major centers of business, finance, technology and government. The firm has offices in New York, Washington, D.C., Boston, Chicago, San Francisco, Silicon Valley, London, Hong Kong, Shanghai, Tokyo and Seoul.
Three of a Kind: FDA Guidance Documents Provide Recommendations on Non-Traditional Clinical Trial Designs
On September 16-17, 2024, FDA issued three guidance documents (one final and two drafts) as part of the Agency’s ongoing efforts to modernize its policies for the conduct of clinical trials.
FDA Takes Next Step In Advancing Diversity In Clinical Studies
On June 26, 2024, the U.S. Food and Drug Administration ("FDA") released its much-anticipated draft guidance for industry entitled "Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies" (the "Draft Guidance"), which delineates FDA's expectations regarding the types of clinical studies for which a Diversity Action Plan ("DAP") is required as well as the format, content, and process for submitting DAPs to FDA.
FDA Takes Next Step in Advancing Diversity in Clinical Studies
On June 26, 2024, the U.S. Food and Drug Administration (“FDA”) released its much-anticipated draft guidance for industry entitled “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies” (the “Draft Guidance”), which delineates FDA’s expectations regarding the types of clinical studies for which a Diversity Action Plan (“DAP”) is required as well as the format, content, and process for submitting DAPs to FDA.
Non-Binding Guidance: FDA Regulatory & Enforcement Risks Relevant To Academic Medical Centers, Health Systems And Research Institutions (Podcast)
On this episode of Ropes & Gray's podcast series, Non-binding Guidance, counsel Steve Sencer moderates a discussion on how FDA regulatory issues may impact academic medical centers (AMCs), health systems, and universities/research institutions. Joined by partner David Peloquin, and counsel Sarah Blankstein and Beth Weinman, the episode explores the complexities of FDA regulation, the potential risks, and the best practices to mitigate them.
Non-binding Guidance: FDA Regulatory & Enforcement Risks Relevant to Academic Medical Centers, Health Systems and Research Institutions
Click here to listen to the audio On this episode of Ropes & Gray’s podcast series, Non-binding Guidance, counsel Steve Sencer moderates a discussion on how FDA regulatory issues may impact academic medical centers (AMCs), health systems, and universities/research institutions. Joined by partner David Peloquin, and counsel Sarah Blankstein and Beth Weinman, the episode explores the complexities of FDA regulation, the potential risks, and the best practices to mitigate them.
DOJ Proposes Rescheduling Marijuana, But the Outlook for Finalization Is Hazy
On May 21, 2024, the U.S. Department of Justice (“DOJ”) published its long-anticipated notice of proposed rulemaking (“NPRM”) announcing its intention to reschedule marijuana. The rule proposes to move botanical cannabis (Cannabis sativa L.) with tetrahydrocannabinol (“THC”) content over 0.3% from schedule I to schedule III, a less-restrictive schedule, under the Controlled Substances Act (“CSA”).
U.S. Enacts Sweeping Legislation to Restrict Flows of Sensitive Data to the People’s Republic of China and Other Foreign Adversaries
On April 24, President Biden signed a sweeping foreign aid bill into law, which included a critical provision covering privacy and data transfers known as the Protecting Americans’ Data from Foreign Adversaries Act (“PADFA”). This Act is separate from the TikTok divestment portion of the legislation, which has received far greater attention in the press.
In Bloomberg Law Article, Attorneys Analyze Washington State's New Privacy Law That Safeguards Consumer Health Data
In a Bloomberg Law article, attorneys examined Washington State’s comprehensive new privacy law, the My Health My Data Act, the first state law that specifically safeguards consumer health data. The article discusses the new law’s scope, applicability, and ensuing company obligations.
Inching Toward Harmonization: FDA Finalizes Rule On IRB Waiver Of Informed Consent For Minimal Risk Studies
On December 21, 2023, the U.S. Food and Drug Administration ("FDA") published a final rule to allow institutional review boards ("IRBs") to waive or alter informed consent for certain clinical investigations that pose no more than minimal risk to human subjects and include appropriate safeguards to protect the rights, safety, and welfare of human subjects (the "Final Rule").1 The Final Rule follows a proposed rule issued in November 2018,2 which we discussed in a previous Alert.
Inching Toward Harmonization: FDA Finalizes Rule on IRB Waiver of Informed Consent for Minimal Risk Studies
On December 21, 2023, the U.S. Food and Drug Administration (“FDA”) published a final rule to allow institutional review boards (“IRBs”) to waive or alter informed consent for certain clinical investigations that pose no more than minimal risk to human subjects and include appropriate safeguards to protect the rights, safety, and welfare of human subjects (the “Final Rule”).1 The Final Rule follows a proposed rule issued in November 2018,2 which we discussed in a previous Alert.
Unpacking NIST's Guidance On Genomic Data Cybersecurity
ADVERTISEMENT Don't want ads? Subscribe or login now. By Christine Moundas, David Peloquin and Elana Bengualid (January 9, 2024, 5:53 PM EST) -- On Dec. 20, 2023, the National Institute of Standards and Technology National Cybersecurity Center of Excellence published its final internal report on cybersecurity of genomic data.[1]... A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence.
Unpacking NIST's Guidance On Genomic Data Cybersecurity
ADVERTISEMENT Don't want ads? Subscribe or login now. By Christine Moundas, David Peloquin and Elana Bengualid (January 9, 2024, 5:53 PM EST) -- On Dec. 20, 2023, the National Institute of Standards and Technology National Cybersecurity Center of Excellence published its final internal report on cybersecurity of genomic data.[1]... A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence.
NIST Cybersecurity Center of Excellence – Cybersecurity of Genomic Data Report
On December 20, 2023, the National Institute of Standards and Technology (“NIST”) National Cybersecurity Center of Excellence (“NCCoE”) published its Cybersecurity of Genomic Data report (the “Report”). The Report aims to assist organizations in protecting against misuse of genomic data and enabling secure collaborative innovations.
NIST Cybersecurity Center of Excellence - Cybersecurity of Genomic Data Report
On December 20, 2023, the National Institute of Standards and Technology (“NIST”) National Cybersecurity Center of Excellence (“NCCoE”) published its Cybersecurity of Genomic Data report (the “Report”). The Report aims to assist organizations in protecting against misuse of genomic data and enabling secure collaborative innovations.
FDA Finalizes Guidance On Informed Consent For Clinical Investigations
On August 15, 2023, the U.S. Food and Drug Administration ("FDA") issued a new guidance document on informed consent (the "Final Guidance").1 This guidance finalizes the draft "Informed Consent Information Sheet" from 2014 (the "Draft Guidance") and supersedes FDA's guidance from 1998, "A Guide to Informed Consent."2 FDA's issuance of the Final Guidance follows FDA's continuing efforts in recent years to modernize and streamline the clinical trial enterprise.
FDA Finalizes Guidance on Informed Consent for Clinical Investigations
On August 15, 2023, the U.S. Food and Drug Administration (“FDA”) issued a new guidance document on informed consent (the “Final Guidance”).1 This guidance finalizes the draft “Informed Consent Information Sheet” from 2014 (the “Draft Guidance”) and supersedes FDA’s guidance from 1998, “A Guide to Informed Consent.”2 FDA’s issuance of the Final Guidance follows FDA’s continuing efforts in recent years to modernize and streamline the clinical trial enterprise.
Decoding Digital Health: Trans-Atlantic Transfers of Health Data
The Ropes & Gray Decoding Digital Health podcast series discusses the digital health industry and related legal, business and regulatory issues. In this episode, Digital Health Initiative co-lead and health care partner, Christine Moundas, interviews health care partner and member of the digital health group, David Peloquin.
Decoding Digital Health: Trans-Atlantic Transfers of Health Data
Click here to listen to the audio The Ropes & Gray Decoding Digital Health podcast series discusses the digital health industry and related legal, business and regulatory issues. In this episode, Digital Health Initiative co-lead and health care partner, Christine Moundas, interviews health care partner and member of the digital health group, David Peloquin.
Congress Enacts Legislation Requiring Guidance on Clinical Research Diversity and Modernization
On December 29, 2022, President Biden signed into law the Consolidated Appropriations Act, 2023 (H.R. 2617), an omnibus appropriations bill to fund the U.S. government through fiscal year 2023. Included in the omnibus bill is the Food and Drug Omnibus Reform Act of 2022 (“FDORA”), which includes several provisions intended to promote diversity in clinical trial enrollment, encourage the growth of decentralized clinical trials, and streamline clinical trials.
White House Issues Executive Order Outlining Key Points of the Transatlantic Data Privacy Framework
On 7 October 2022, the White House issued an Executive Order, as well as an accompanying Fact Sheet, which sets out the foundations for the Transatlantic Data Privacy Framework (“Framework”).
HHS Reverses Course On LDTs: COVID-19 LDTs Again Require FDA Premarket Review
To print this article, all you need is to be registered or login on Mondaq.com. On November 15, 2021, the U.S. Department of Health and Human Services ("HHS") and the Food and Drug Administration ("FDA") issued several policy changes governing the regulation of Laboratory Developed Tests ("LDTs").
Demystifying Schrems II for the Cross-Border Transfer of Clinical Research Data
The Courts of Justice of the European Union (CJEU) held in its July 2020 Schrems II decision that, in order for entities in other countries to import personal data from the European Economic Area (EEA), the importer must be able to provide data protections ‘essentially equivalent’ to those the EEA offers under its General Data Protection Regulation.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with David
Contact David, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack